

Form PTO-1390

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

P21620.P01

P21620

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371U.S. APPLICATION NO. (If known, see 37 CFR
1.5)

09/926358

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/JP00/02596

20 April 2000

23 April 1999

TITLE OF INVENTION

LIPOsome BONDED WITH ANTIBODY AND POLYALKYLENE GLYCOL

APPLICANT(S) FOR DO/EO/US

Toshiaki TAGAWA and Saiko HOSOKAWA

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information.

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).
4. ☒ The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3))
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
"Unexecuted"
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (U.S.C. 371(c)(5)).

Items 11 to 16 below concern other document(s) or information included:

11. Assignee: MITSUBISHI CHEMICAL CORPORATION of Tokyo, JAPAN
12. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
13. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
14. ☒ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ Figure of Drawing to be published _____
18. ☒ Other items or information:
Cover Sheet and International Application as published in Japanese.
PCT/RO/101-PCT Request(in Japanese).
PCT/IPEA/408(in Japanese).
PCT/IPEA/409.
PCT/IB/301.
PCT/IB/304.
PCT/IB/308.
PCT/IB/332.
PCT/IB/338.
PCT/ISA/210(in English and Japanese).
Cover Letter under 35 USC 371 and 1.495.
Claim of Priority.

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/ 926358

INTERNATIONAL APPLICATION NO.

PCT/JP00/02596

ATTORNEY'S DOCKET NUMBER

P21620

19. The following fees are submitted:

Basic National Fee (37 CFR 1.492(a)(1)-(5)):

Search report has been prepared by the EPO or JPO. \$ 890.00

International preliminary examination fee paid to USPTO (37 CFR 1.482). \$ 710.00

No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)). \$ 740.00

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO. \$1,040.00

International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4). \$ 100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

CALCULATIONS

PTO USE ONLY

\$890.00

Surcharge of \$130.00 for furnishing the oath or declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

Claims	Number Filed	Number Extra	RATE		
Total Claims	28 - 20 =	8	X \$18.00	\$144.00	
Independent Claims	3 - 3 =	0	X \$84.00	\$0.00	
Multiple dependent claim(s) (if applicable)			+ \$280.00	\$0.00	

TOTAL OF ABOVE CALCULATIONS =

\$1034.00

Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.

\$

SUBTOTAL =

\$1034.00

Processing fee of \$130.00 for furnishing the English translation later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(f)).

+

Extension of Time fee in the amount of \$

TOTAL NATIONAL FEE =

\$1034.00

Fee for recording the enclosed assignment (37 CFR 1.21(h). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property

+

TOTAL FEES ENCLOSED =

\$1034.00

Amount to be refunded

\$

Charged

\$

a. ☒ A check in the amount of \$1034.00 to cover the above fees is enclosed.b. ☐ Please charge my Deposit Account No. _____ in the amount of \$_____ to cover the above fees.c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0089.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO CUSTOMER NO. 7055
 AT THE PRESENT ADDRESS OF:
 Bruce H. Bernstein
 GREENBLUM & BERNSTEIN, P.L.C.
 1941 Roland Clarke Place
 Reston, VA 20191
 (703) 716-1191

**007055**

PATENT AND TRADEMARK OFFICE

Bruce H. Bernstein
 SIGNATURE
 Bruce H. Bernstein
 NAME

29.027

REGISTRATION NUMBER

P21620.A01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Toshiaki TAGAWA et al.

Serial No : Not Yet Assigned (National Stage of PCT/JP00/02596)

Filed : Concurrently Herewith (International Filing Date April 20, 2000)

For : LIPOSOME BONDED WITH ANTIBODY AND
POLYALKYLENE GLYCOL**PRELIMINARY AMENDMENT**Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

Prior to calculation of the filing fees and the examination of the above-identified patent application on the merits, the Examiner is respectfully requested to amend the claims as follows:

IN THE CLAIMS

Please amend the claims as follows (a marked-up copy of the claim amendments is provided as an attachment to this Amendment):

3. (Amended-Clean Text) The liposome according to claim 1, which is obtained by reacting a maleimide group of the maleimidated lipid with the compound containing a polyalkylene glycol moiety introduced with a thiol group.

4. (Amended-Clean Text) The liposome according to claim 1, wherein the compound is bonded to a surface of the liposome.

5. (Amended-Clean Text) The liposome according to claim 1, wherein the polyalkylene glycol is polyethylene glycol.

9. (Amended-Clean Text) The liposome according to claim 1, wherein an antibody is further bonded on a surface of the liposome.

12. (Amended-Clean Text) The liposome according to claim 10, which is obtained by reacting a liposome having a maleimide group and a sulfur-containing group deriving from the antibody to form a thioether bond.

13. (Amended-Clean Text) The liposome according to claim 10, wherein the antibody is a GAH antibody.

14. (Amended-Clean Text) The liposome according to claim 10, wherein the antibody is a $F(ab')_2$ antibody fragment.

P21620.A01

15. (Amended-Clean Text) The liposome according to claim 10, wherein a compound containing a polyalkylene glycol moiety is further bonded to a surface of the liposome.

18. (Amended-Clean Text) The liposome according to claim 16, wherein the compound is bonded to a surface of the liposome.

19. (Amended-Clean Text) The liposome according to claim 16, wherein the polyalkylene glycol is polyethylene glycol.

23. (Amended-Clean Text) The liposome according to claim 16, which is a liposome obtained by reacting a liposome having a maleimide group and a sulfur-containing group deriving from the antibody to form a thioether bond.

24. (Amended-Clean Text) The liposome according to claim 16, wherein the antibody is a GAH antibody.

25. (Amended-Clean Text) The liposome according to claim 16, wherein the antibody is a $F(ab')_2$ antibody fragment.

P21620.A01

26. (Amended-Clean Text) A medicament for treatment of cancer according to claim 1.


28. (Amended-Clean Text) A method for treatment of cancer which comprises the use of the liposome according to claim 1.

REMARKS

By the above amendment, the claims have been amended to delete multiple dependency.

If there should be any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,
Toshiaki TAGAWA et al.


Bruce H. Bernstein
Reg. No. 29,027

October 22, 2001
GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

MARKED-UP COPY OF AMENDED CLAIMS

3. (Amended) The liposome according to claim 1 [or claim 2], which is obtained by reacting a maleimide group of the maleimidated lipid with the compound containing a polyalkylene glycol moiety introduced with a thiol group.

4. (Amended) The liposome according to claim 1 [any one of claims 1 to 3], wherein the compound is bonded to a surface of the liposome.

5. (Amended) The liposome according to claim 1 [any one of claims 1 to 4], wherein the polyalkylene glycol is polyethylene glycol.

9. (Amended) The liposome according to claim 1 [any one of claims 1 to 8], wherein an antibody is further bonded on a surface of the liposome.

12. (Amended) The liposome according to claim 10 [or claim 11], which is obtained by reacting a liposome having a maleimide group and a sulfur-containing group deriving from the antibody to form a thioether bond.

13. (Amended) The liposome according to claim 10 [any one of claims 10 to 12], wherein the antibody is a GAH antibody.

P21620.A01

14. (Amended) The liposome according to claim 10 [any one of claims 10 to 13], wherein the antibody is a F(ab')₂ antibody fragment.

15. (Amended) The liposome according to claim 10 [any one of claims 10 to 14], wherein a compound containing a polyalkylene glycol moiety is further bonded to a surface of the liposome.

18. (Amended) The liposome according to claim 16 [or claim 17], wherein the compound is bonded to a surface of the liposome.

19. (Amended) The liposome according to claim 16 [any one of claims 16 to 18], wherein the polyalkylene glycol is polyethylene glycol.

23. (Amended) The liposome according to claim 16 [any one of claims 16 to 22], which is a liposome obtained by reacting a liposome having a maleimide group and a sulfur-containing group deriving from the antibody to form a thioether bond.

24. (Amended) The liposome according to claim 16 [any one of claims 16 to 23], wherein the antibody is a GAH antibody.

P21620.A01

25. (Amended) The liposome according to claim 16 [any one of claims 16 to 24], wherein the antibody is a F(ab')₂ antibody fragment.

26. (Amended) A medicament for treatment of cancer according to claim 1 [any one of claims 1 to 25].

28. (Amended) A method for treatment of cancer which comprises the use of the liposome according to claim 1 [any one of claims 1 to 27].

4/pv

SPECIFICATION

LIPOSOME BONDED WITH ANTIBODY AND POLYALKYLENE GLYCOL

Technical Field

The present invention relates to a liposome. More specifically, the present invention relates to a liposome bonded with an antibody and/or polyalkylene glycol, which has superior blood retention and therapeutic effect.

Background Art

As means for transporting a large amount of a drug to a specific site, a method has been proposed which includes the step of encapsulating a drug in a liposome and bonding an antibody to surface of the liposome. In the field of cancer treatment, in particular, a number of reports have been made on efficacy of an antibody-bonded liposome in which an antitumor agent is encapsulated (Konno et al., Cancer Res., 47, 4471, 1987; Japanese Patent Unexamined Publication (Kokai) No. 58-134032). Moreover, a method of bonding polyethylene glycol to a liposome has been proposed as a method for solving problems with a liposome, i.e., leakage of encapsulated substances, agglutination of liposomes, capture in reticuloendothelial organs and the like (Japanese Patent Unexamined Publication (Kokai) Nos. 1-249717 and 2-149512; Klibanov et al., FEBS Lett., 268, 235, 1990).

Japanese Patent Unexamined Publication (Kokai) No. 4-346918 discloses a protein-bonded liposome encapsulating a drug, wherein the liposome is characterized to have a protein and a residue of compound containing a polyalkylene glycol moiety both of which are bound through their respective thiol groups to maleimide groups on the surface of the liposome encapsulating a drug. This liposome is produced by reacting a thiol group bonded to the antibody and a thiol group bonded to the compound containing a polyalkylene glycol moiety with the maleimide groups on the liposome surface. The liposome has a feature in that non-specific uptake in the reticuloendothelial system, such as in liver and spleen as observed in conventional liposomes, is suppressed and selective chemotherapy can be achieved.

In the above patent publication, any specific amount of the compound

0926358-010702

204070-8583550

containing a polyalkylene glycol moiety bound to the liposome is not explained. The document, however, discloses that 0.1 to 20 mole % of thiolated antibodies are reacted with 1 mole of maleimide groups (maleimidated lipids), and then an excessive amount of, preferably two or more fold amount of the compound containing a thiolated polyalkylene glycol moiety based on the remaining maleimide groups is added to obtain an antibody-bonded liposome modified with polyalkylene glycol (Paragraph 0016). In the method for preparing a liposome specifically described in the examples, 5 micromole of a compound containing a thiolated polyethylene glycol moiety is reacted with 100 mg of total lipids (corresponding to 3.1 mole% to the total lipids). It is considered that a liposome modified with a theoretical amount of polyethylene glycol (i.e., the amount of the maleimide groups remaining on the liposome surface) was obtained by reacting a large excessive amount of the compound containing a thiolated polyethylene glycol moiety based on the lipids.

Further, in the above patent publication, any specific amount of the antibodies bound to the liposome is not explained. The publication explains that 0.1 to 20 mole% of the thiolated antibodies were reacted with 1 mole of maleimide group of the maleimidated lipid (corresponding to 0.3 to 60 mg per 100 mg of the total lipids). In the method for preparing the liposome specifically described in the examples, 5 mg of the antibodies were bonded to 100 mg of the total lipids (corresponding to 1.7 mole% based on the maleimidated lipids). However, the above publication contains no specific disclosure as to an amount of bonding other than the above.

Disclosure of the Invention

On the basis of the liposome described in Japanese Patent Unexamined Publication (Kokai) No. 4-346918, the inventors of the present invention conducted various studies to provide a liposome having higher blood retention and superior safety. As a result, it was surprisingly found that, when an amount of polyalkylene glycol that modifies the liposome was reduced below the theoretical value (i.e., the amount of the maleimide groups remaining on the liposome surface) in the liposome described in Japanese Patent Laid-Open Publication (Kokai) No. 4-346918, almost the same level of blood retention as that of the known liposome was obtained by the liposome having a modification amount less than the theoretical value.

Moreover, on the basis of the liposome described in Japanese Patent Unexamined Publication (Kokai) No. 4-346918, the inventors of the present invention further conducted studies to provide a liposome that can achieve a higher therapeutic effect. As a result, it was surprisingly found that, when the amount of the bonded antibodies of the liposome described in Japanese Patent Unexamined Publication (Kokai) No. 4-346918 was reduced, much higher therapeutic effect was achieved than that of the liposome described in the examples of the above publication. The present invention was achieved on the basis of these findings.

The present invention thus provides a liposome wherein a compound containing a polyalkylene glycol moiety is bonded through a thioether group to a liposome comprising lipids whose partial component has maleimidated terminal, wherein an amount of the bonded compound is 15 to 50 mole% based on one mole of the maleimidated lipid contained in the liposome; the aforementioned liposome wherein the amount of the bonded compound is 15 to 30 mole% based on one mole of the maleimidated lipids; the aforementioned liposome which is obtained by reacting a maleimide group in the maleimidated lipid with the compound containing a polyalkylene glycol moiety introduced with a thiol group; the aforementioned liposome wherein the compound is bonded to a surface of the liposome; the aforementioned liposome wherein the polyalkylene glycol is polyethylene glycol; the aforementioned liposome wherein the compound has two polyethylene glycol groups; the aforementioned liposome wherein the polyethylene glycol has a molecular weight of 2,000 to 7,000 Da; the aforementioned liposome wherein the polyethylene glycol has a molecular weight of about 5,000 Da; and the aforementioned liposome wherein an antibody is further bonded on a surface of the liposome.

The present invention further provides a liposome wherein an antibody is bonded through a thioether group to a liposome comprising lipids whose partial component has maleimidated terminal, wherein an amount of the bonded antibody is 0.1 to 2 mole% based on one mole of the maleimidated lipids contained in the liposome; the aforementioned liposome wherein an amount of the bonded antibody is 0.4 to 0.7 mole% based on one mole of the maleimidated lipids; the aforementioned liposome which is obtained by reacting a liposome having a maleimide group and a sulfur-containing group deriving from the antibody to form a thioether bond; the

2020-09-29 09:56:35

aforementioned liposome wherein the antibody is a GAH antibody; the aforementioned liposome wherein the antibody is a $F(ab')_2$ antibody fragment; and the aforementioned liposome wherein a compound containing a polyalkylene glycol moiety is further bonded to a surface of the liposome.

The present invention also provides a liposome wherein a compound containing a polyalkylene glycol moiety and an antibody are bonded through thioether groups to a liposome comprising lipids whose partial component has maleimidated terminal, wherein an amount of the bonded compound is 15 to 30 mole% and an amount of the bonded antibody is 0.4 to 0.7 mole% based on one mole of the maleimidated lipids contained in the liposome; the aforementioned liposome which is obtained by reacting a maleimide group in the maleimidated lipid with the compound containing a polyalkylene glycol moiety introduced with a thiol group; the aforementioned liposome wherein the compound is bonded to a surface of the liposome; the aforementioned liposome wherein the polyalkylene glycol is polyethylene glycol; the aforementioned liposome wherein the compound has two polyethylene glycol groups; the aforementioned liposome wherein the polyethylene glycol has a molecular weight of 2,000 to 7,000 Da; the aforementioned liposome wherein the polyethylene glycol has a molecular weight of about 5,000 Da; the aforementioned liposome which is a liposome obtained by reacting a liposome having a maleimide group and a sulfur-containing group deriving from the antibody to form a thioether bond; the aforementioned liposome wherein the antibody is a GAH antibody; and the aforementioned liposome wherein the antibody is a $F(ab')_2$ antibody fragment.

The present invention also provides the aforementioned liposome, which is an anticancer agent; the aforementioned anticancer agent wherein the cancer is stomach cancer or colon cancer; and a method for treating cancer by using the aforementioned liposome.

Brief Description of the Drawings

Fig. 1 shows correlation between the amount of polyethylene glycol bonded to a liposome (encapsulating doxorubicin (DXR) and bonded with no antibody) and the DXR concentration in plasma. The horizontal axis indicates the PEG amount (in mole% based on one mole of DPPC). The PEG amount in mole% based on the total lipid and

maleimidated DPPE are 0.16 and 8.9 (0.25); 0.32 and 17.8 (0.5); 0.48 and 26.7 (0.75); 0.64 and 35.6 (1) and 0.81 and 45 (1.25), respectively (the parenthesized values indicate mole% based on one mole of DPPC).

Fig. 2 shows correlation between the amount of polyethylene glycol bonded to a liposome (encapsulating DXR and bonded with antibodies) and the DXR concentration in plasma. The horizontal axis indicates the PEG amount (the PEG amount (mg) per 100 mg of lipids). The PEG amounts in mole% based on one mole of DPPC, total lipids and maleimidated DPPE are 0.25, 0.16 and 8 (2.5); 0.50, 0.31 and 17 (5); 0.75, 0.47 and 26 (7.5); and 1.0, 0.62 and 34 (10), respectively (the parenthesized values indicate the PEG amounts (mg) per 100 mg of lipids).

Fig. 3 shows correlation between the amount of antibodies bonded to a liposome (encapsulating DXR) and tumor inhibitory effect (% T/C).

Fig. 4 shows correlation between the DXR amount in plasma (blood retention) and the amount of bonded antibodies in samples in which the amount of the bonded antibodies is 2 mg or more per 100 mg of lipids.

Best Mode for Carrying out the Invention

Examples of lipids constituting the liposome of the present invention include natural lecithins (for example, egg yolk lecithin and soybean lecithin), phospholipids such as dipalmitoylphosphatidylcholine (DPPC), dimyristoylphosphatidylcholine (DMPC), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dimyristoylphosphatidylethanolamine (DMPE), dipalmitoylphosphatidylethanolamine (DPPE), dioleoylphosphatidylethanolamine (DOPE), dipalmitoylphosphatidic acid (DPPA), dipalmitoylphosphatidyl glycerol (DPPG) and dimyristoylphosphatidic acid (DMPA), glycolipids such as sphingoglycolipids and glyceroglycolipids, fatty acids, dialkyldimethylammonium amphiphiles, polyglycerol alkyl ethers and polyoxyethylene alkyl ethers (Liposome Technology, 2nd edition, vol. 1, 141, 1993), alkylglycosides, alkylmethylglucamide, alkyl sucrose esters, dialkylpolyoxyethylene ether, dialkylpolyglycerol ether and so forth (Liposome Technology, 2nd edition, vol. 1, 141, 1993), amphipathic block copolymers such as polyoxyethylene-polylactic acid (International Patent Unexamined Publication in Japanese (Kohyo) No. 6-508831) and the like. However, lipids are not limited to these examples. These lipids may be

used alone or in combination of two or more kinds, and can also be used in combination with a non-polar substance such as cholesterol or a cholesterol derivative such as DC-chol (3 β -[N-(N',N'-dimethylaminoethyl)carbamoyl]cholesterol).

In the liposome of the present invention, a maleimidedated lipid (hereinafter referred to as "maleimidedated lipid") such as maleimidedated phosphatidylethanolamine is required to be used as a part of the lipid components for bonding of a compound containing polyalkylene glycol and, as required, a protein such as antibodies. A ratio of the maleimidedated lipid to the total lipids is usually about 0.5 to 10 mole%.

Maleimidedated phosphatidylethanolamine will be explained as an example. This compound is obtained by reacting a maleimido-containing compound having reactivity with an amino group of phosphatidylethanolamine (PE). The maleimido-containing compound may contain a residue such as a caproyl group, a benzoyl group or a phenylbutyryl group. Examples of such a compound include N-(ϵ -maleimidocaproyloxy)succinimide, N-succinimidyl-4-(p-maleimidophenyl)-butylate, N-succinimidyl-4-(p-maleimidophenyl)propionate, N-(γ -maleimido-butyryloxy)succinimide and the like. As PE, phosphatidylethanolamines such as dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphatidylethanolamine (DMPE) or dioleoylphosphatidylethanolamine (DOPE) can be used, and DPPE is preferred. Further, a charged substance such as stearylamine or dicetylphosphate may also be contained as a lipid component. The liposome of the present invention may be a fusiogenic liposome incorporating a part or whole of virus, for example, a liposome fused with Sendai virus.

For a typical liposome, for example, a lipid composition containing 0.3 to 1 mole, preferably, 0.4 to 0.6 mole of cholesterol and 0.01 to 0.2 mole, preferably 0.02 to 0.1 mole, more preferably 0.02 to 0.05 mole, of maleimidedated phosphatidylethanolamine per mole of phosphatidylcholine can be used. When phosphatidic acid is added, a lipid composition containing 0.4 mole or less, preferably 0.15 mole or less of phosphatidic acid can be used.

Methods for preparing the liposome of the present invention are not particularly limited and any method available to those skilled in the art can be used. Further, a structure of the liposome of the present invention is not particularly limited and the liposome may be in any structure. For example, the liposome may be any of a

multilamellar liposome (MLV) obtained by adding an aqueous solution to a thin lipid membrane formed on a glass wall and subjecting the membrane to mechanical shaking; a small unilamellar liposome (SUV) obtained by the sonication method, the ethanol injection method or the French press method; and a large unilamellar liposome (LUV) obtained by the surfactant removing method, the reversed-phase evaporation method (Liposome, Sunamoto J. et al., Nankodo Co., Ltd., 1998), or the extrusion method in which MLV is extruded through a membrane having a uniform pore size by pressurization (Liposome Technology, 2nd edition, vol.1, 141, 1993). The particle diameter of the liposome is, for example, 300 nm or smaller, preferably, about 30 to 200 nm.

A medicament can be encapsulated in the liposome of the present invention. Types of the medicament are not particularly limited. For example, usable medicaments include antitumor agents such as doxorubicin (adriamycin), daunomycin, vinblastine, cisplatin and 5-fluorouracil (5-FU); adrenalin blocking agents such as timolol; antihypertensive agents such as clonidine; antiemetic drugs such as procainamide; antimalarial agents such as chloroquine; and pharmaceutically acceptable salts and derivatives thereof; radioactive substances such as rhenium 186, iodine 131 and yttrium 90; physiologically active substances such as ricin A, diphtheria toxin and TNF and DNA encoding the substance and the like. However, medicaments that can be encapsulated in the liposome of the present invention are not limited to these examples.

As pharmaceutically acceptable salts of the aforementioned medicaments, preferred examples include salts with pharmaceutically acceptable multivalent anionic substances such as citrates, tartrates, glutamates, and salts with derivatives thereof. As the medicament encapsulated in the liposome of the present invention, antitumor agents are preferred. In addition to a therapeutic medicament, a medicament for diagnosis can be encapsulated in the liposome of the present invention. Examples of the diagnostic medicament include radioactive isotopes, for example, imaging agents such as indium and technetium; contrast media such as iodine and gadolinium; enzymes such as horseradish peroxidase, alkaline phosphatase and β -galactosidase; fluorescent substances such as europium derivatives; luminescent substances such as N-methylacridium derivatives and the like. However, medicaments are not limited

to these examples.

Methods for encapsulating the medicaments into the liposome are not particularly limited, and any method available to those skilled in the art can be applied. For example, upon formulation of a liposome, a medicament can be added as an aqueous solution and encapsulated in the liposome. Further, after formulation of the liposome, a method can be applied in which a concentration gradient such as a pH gradient is formed across a vesicle and this potential is used as a driving force to incorporate an ionizable drug into the liposome (Cancer Res., 49, 5922, 1989; BBA, 455, 269, 1976).

The liposome of the present invention is characterized in that the liposome is modified with a compound containing a polyalkylene glycol moiety and further modified with a specific amount of an antibody. As the polyalkylene glycol, for example, polyethylene glycol (PEG), polypropylene glycol or the like can be used, and polyethylene glycol is preferred. When polyethylene glycol is used, those having a molecular weight of about 2,000 to 7,000 Da, preferably about 5,000 Da, can be used.

The liposome of the present invention is in a structure wherein the compound containing a polyalkylene glycol is bonded through a thioether bond to a maleimided lipid on the liposome surface. The liposome bonded with polyalkylene glycol can usually be prepared by introducing a thiol group into a compound containing polyalkylene glycol and then reacting the compound with a maleimide group on a liposome. Examples of the compound containing polyalkylene glycol generally include a compound that has a polyethylene glycol group and a terminal that can be thiolated or a compound having a mercapto group at a terminal thereof. Specifically, examples include a compound in which a polyalkylene glycol group is bonded to triazine and a compound in which the triazine is further substituted with an amino acid or the like. The compound may have two polyalkylene glycol groups (two-chain type).

When polyethylene glycol is used as the polyalkylene glycol, applicable methods include, for example, a method of condensing monomethoxypolyoxyethyleneamine and any of various thiolcarboxylic acids by dehydration; a method of introducing a pyridyldithiopropionyl group into monomethoxypolyoxyethyleneamine using SPDP and further reducing the product; a method of introducing a thiol group into monomethoxypolyoxyethyleneamine by using iminothiolane; a method of bonding

an active ester of monomethoxypolyoxyethylenecarboxylic acid and any of various thiolamines; a method of condensing a polyethylene glycol triazine derivative with a thiolamine or the like. More specifically, a cysteine-bonded activated PEG 2 can be obtained by reacting 2,4-bis(polyethylene glycol)-6-chloro-s-triazine (activated PEG 2, Seikagaku Corporation) with cystine and further reducing the product.

An introduced amount of the compound containing a polyalkylene glycol moiety in the liposome of the present invention is not particularly limited, and an excessive amount of the compound can be reacted with the remaining maleimidated lipids. A preferred introduced amount of the polyalkylene glycol is about 0.28 to 0.90 mole%, more preferably about 0.28 to 0.56 mole%, based on the total lipids, about 15 to 50 mole%, more preferably about 15 to 30 mole%, based on the maleimidated lipids, and about 0.44 to 1.45 mole%, more preferably about 0.44 to 0.89 mole%, based on DPPC.

The liposome of the present invention may be modified with a protein, for example, an antibody. As a protein, for example, various physiologically active substances such as antibodies, FGF and EGF can be used. Preferably, antibodies can be used. As the antibody, an antibody per se or a fragment of an antibody, a derivative of an antibody or the like can be used, and either an antibody per se or an antibody fragment may be used as the antibody. The term "antibody" used in the specification encompasses derived or modified antibodies and the like as well as antibodies per se and fragments of antibodies, and the term should be interpreted in the broadest sense. As the antibody, an antibody having reactivity with tissues, cells, bacteria, viruses or the like, which are targets of therapeutic treatment, may also be used. For example, polyclonal antibodies deriving from various animals, mouse monoclonal antibodies, human-mouse chimeric antibodies, human monoclonal antibodies and the like can be used. A human monoclonal antibody is more preferred, since the antibody is not a protein from a heterogenous animal. As the antibody, the human monoclonal antibody described in Japanese Patent Unexamined Publication (Kokai) No. 5-304987 (GAH antibody) can be preferably used. For example, a liposome modified with a GAH antibody can be prepared according to the method specifically described in Example 7 of the above publication. As described in Japanese Patent Unexamined Publication (Kokai) No. 5-304987, since the GAH

antibody has reactivity with stomach cancer and colon cancer, the liposome of the present invention is useful as an anticancer agent for treatment of stomach cancer, colon cancer and the like. A liposome having an excellent therapeutic effect can be produced by appropriately choosing a combination of the type of an antibody and a medicament to be encapsulated.

After a thiol group is introduced to an antibody, a liposome can be modified with the antibody by reacting a maleimide group on the liposome with the thiolated antibody. The addition of a thiol group to the antibody is carried out by reacting a compound ordinarily used for thiolation of a protein such as N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP) (Carlsson, J., et al., *Biochem. J.*, 173, 723, 1978), iminothiolane or mercaptoalkylimidate (Traut, R.R., et al., *Biochemistry*, 12, 3266, 1973) with an amino group of the antibody. Further, an endogenous dithiol group of an antibody can be reduced and reacted as a thiol group. From a viewpoint of sustained antibody activity, the method of using an endogenous thiol group is preferred.

For example, when IgG is used, an $F(ab')_2$ fragment can be obtained by using an enzyme such as pepsin, and then a thiol group, generated in a Fab' fragment which is obtained by reducing the $F(ab')_2$ fragment by using dithiothreitol, can be utilized in the bonding reaction with a liposome (Martin, F.J. et al., *Biochemistry*, 20, 4229, 1981). Where IgM is used, a thiol group of an Fc region of IgMs obtained by reducing the J chain under a mild condition can be utilized for bonding with a liposome according to the method of Mirror et al. (*J. Biol. Chem.*, 257, 286, 1965). When the GAH antibody described in Japanese Patent Unexamined Publication (Kokai) No. 5-304987 is used, an $F(ab')_2$ fragment is preferably used. Bonding of a protein such as an antibody added with a thiol group and a liposome containing a maleimide group is achieved by a reaction in a neutral buffer (pH 6.5 to 7.5) for 2 to 16 hours.

A liposome bonded with an antibody and a compound containing a polyalkylene glycol moiety is a most preferred embodiment of the present invention. To produce this liposome, a thiolated antibody is reacted with a liposome having a maleimide group in a neutral buffer. For example, thiolated antibodies in an amount of 0.1 mole% (specifically, 0.17 mole%) to about 2 mole% (specifically, 1.5 mole%, 1.8 mole%), preferably 0.4 to 0.7 mole%, can be reacted with one mole of the maleimide

groups (maleimidated lipids) so that 0.5 to 5.3 mg, 0.5 to 4.5 mg, preferably 1.2 to 2 mg, of antibodies are bonded per 100 mg of total lipids constituting the liposome. Then, a compound containing a polyalkylene glycol moiety can be reacted with the remaining maleimide groups to prepare a liposome bonded with the antibody and the compound containing a polyalkylene glycol moiety. More specifically, 15 to 50 mole%, preferably 15 to 30 mole% of a compound containing a thiolated polyalkylene glycol moiety is added to one mole of maleimidated lipid groups (i.e., 0.28 to 0.90 mole%, preferably 0.28 to 0.56 mole% based on the total lipids, and when DPPC is used, 0.44 to 1.45 mole%, preferably 0.44 to 0.89 mole% based on DPPC) to produce a liposome bonded with the antibody and the compound containing a polyalkylene glycol moiety.

As a preferred embodiment of the liposome of the present invention, a liposome is provided, which encapsulates a medicament, preferably an antitumor agent such as doxorubicin, and is bonded with a compound containing a polyethylene glycol moiety and an antitumor antibody. The liposome containing a medicament can be formulated by a known method, for example, the dehydration method (International Patent Unexamined Publication in Japanese (Kohyo) No. 2-502348), the method wherein the liposome is added with a stabilizer and used as a liquid preparation (Japanese Patent Unexamined Publication (Kokai) No. 64-9331), the lyophilization method (Japanese Patent Unexamined Publication (Kokai) No. 64-9931) or the like. The liposome can be administered to a patient through intravascular administration, intravesical administration, intraperitoneal administration, local administration or the like for treatments of various diseases such as cancers. A dose can be appropriately chosen depending on a type of a medicament encapsulated as an active ingredient. For example, when a liposome encapsulating doxorubicin is administered, the liposome can be used in an amount of 50 mg/kg or less, preferably 10 mg/kg or less, more preferably 5 mg/kg or less, as a weight of an active ingredient.

Examples

The present invention will be more specifically explained with reference to the examples. However, the scope of the present invention is not limited to these examples.

Example 1

(1) Preparation of a liposome and encapsulation of a medicament

A lipid mixture (1.6 g) of dipalmitoylphosphatidylcholine (DPPC)/cholesterol/ ϵ -maleimidocaproyldipalmitoylphosphatidylethanolamine (MC-DPPE) (18:10:0.5 in molar ratio) was added with 16 mL of 0.3 M citrate buffer (pH 4.0) and hydrated. Then, freeze and thawing of the mixture was repeated three times using liquid nitrogen and a warm bath at 60°C to produce multilamellar liposomes. The particles were sized to 0.1 μ m by the extrusion method. The resulting liposome solution was neutralized by adding 1 M NaOH dropwise. Then the solution was heated to 60°C and added with an aqueous doxorubicin solution (DXR, also referred to as adriamycin, ADM) at an amount of 0.5 mL of 20 mg/mL per 100 mg of lipids for encapsulation.

(2) Thiolation of an antibody and bonding thereof to liposome (preparation of antibody-bonded liposome)

GAH antibody (a monoclonal antibody described in Japanese Patent Unexamined Publication (Kokai) Nos. 4-346918 and 5-304987 reactive to stomach cancer and colon cancer, 3 mg/mL, 14.4 mL) dissolved in 50 mM phosphate buffer (pH 7.5) containing 1 mM EDTA was added with 92.4 μ L of 3 mg/mL iminothiolane and reacted at 37°C for 1 hour to introduce thiol groups (Biochemistry, 12, 3206, 1973). The reaction mixture was subjected to gel filtration and the buffer was exchanged with 0.1 M phosphate buffer (pH 6.0) containing 1 mM EDTA. Then, the resulting thiolated antibody (0.21 mg, 1.7 mg/mL) per 1 mg liposomal doxorubicin was reacted with the liposome at 25°C for 1 hour to form bonding of the antibody to the liposome.

(3) Thiolation of polyethylene glycol and bonding to liposome (preparation of PEG-bonded liposome)

Cystine was reacted with 2,4-bis(polyethylene glycol)-6-chloro-s-triazine according to the method of Japanese Patent Unexamined Publication (Kokai) No. 4-346918 and then reduced to prepare polyethylene glycol (two-chain type PEG) having thiol groups. More specifically, thiolated PEG (30 mg/mL, a two-chain type PEG having a molecular weight of 2000 (PEG 2000) and a two-chain type PEG having a molecular weight of 5000 (PEG 5000)) were produced by using cystine, and each of

them was added to the above reaction mixture in an amount of 0.18 mL per 1 mL of the reaction mixture for a bonding reaction at 10°C. After 5 to 240 minutes from the start of the reaction, the reaction mixture was sampled and applied to a Sepharose CL6B column to stop the reaction by removing unreacted thiolated PEG to obtain immunoliposomes having different PEG amounts. Non-PEG-bonded immunoliposomes were similarly prepared by subjecting immunoliposomes without the PEG binding treatment to gel filtration using Sepharose CL6B.

(4) Preparation of liposome bonded with antibody and PEG

Liposomes bonded with antibodies and PEG were prepared by reacting the thiolated PEG prepared in the above (3) with the antibody-bonded liposomes prepared in the above (2).

(5) Quantification of bonded PEG

The amount of PEG bonded to immunoliposomes was determined by HPLC. An immunoliposome solution prepared as a SDS solution at a final concentration of 2% was heated at 60°C for 30 minutes to completely solubilize the liposomes. The solution was eluted by using a GPC column (2000SWXL, Tosoh Corporation) with a buffer at pH 7.5 (25 mM NaH₂PO₄, 0.1% SDS, 70% methanol) to separate PEG. The PEG was detected at 215 nm and quantified using area values.

(6) Quantification of DXR

50 μ L of a sample was added to 950 μ L of 50% propanol/0.5 M hydrochloric acid and absorption was measured at 500 nm to quantify DXR.

(7) Quantification of bonded antibody

The antibodies were eluted and separated by using a GPC column (3000SWXL, Tosoh Corporation) with a buffer at pH 7.0 (25 mM NaH₂PO₄, 200 mM Na₂SO₄, 0.1% SDS) in the same manner as in the qualification of PEG. The antibodies were quantified using area values of the antibody peak detected at 280 nm.

(8) Quantification of lipids

Lipids (total amount of DPPC and cholesterol) were quantified by HPLC. The liposomes were loaded on an L-column ODS (4.6 mm × 250 mm, Chemicals Inspection & Testing Institute) and lipids were eluted with tetrahydrofuran (THF)/acetonitrile/water (2:1:1 (v/v/v), 0.1% trifluoroacetic acid). The lipids were detected at 215 nm and quantified from area values of the peaks of DPPC and cholesterol. A sample for quantifying lipids was prepared by adding a 9-fold volume of the above eluent to one volume of the liposome sample.

Example 2: Preparation of PEG-bonded liposome (pharmacokinetic test)

According to the method of Example 1, liposomes were prepared which were introduced with PEG in an amount of 0 to about 0.7 mole% based on one mole of the total lipids constituting the liposomes, 0 to about 1 mole% based on one mole of DPPC, or 0 to about 40 mole% based on one mole of maleimidated lipids (encapsulating DXR with no antibodies bonded, and bonded with PEG 2000 or PEG 5000).

<Table 1>

Liposome	DXR concentration (mg/ml)	PEG amount*	PEG amount**	PEG amount***
1	1.14	0.083 (PEG 5000)	0.13	4.61
2	1.17	0.22 (PEG 5000)	0.34	12.2
3	1.27	0.40 (PEG 5000)	0.63	22.2
4	1.32	0.48 (PEG 5000)	0.75	26.7
5	1.16	0.096 (PEG 2000)	0.15	5.33
6	1.08	0.30 (PEG 2000)	0.47	16.7
7	1.47	0.60 (PEG 2000)	0.94	33.3
8	1.55	0.70 (PEG 2000)	1.09	38.9
9	3.49	-	-	-

* Mole % to total lipids

** Mole % to DPPC

*** Mole % to maleimidated lipid DPPE

Male BALB/cAjl mice (6-week old) were used in experiments. A mouse group consisting of four mice was used for each of the liposomes, and one untreated mouse was used as a blank in the experiment. The liposomes were administered into the tail vein at the dose of 2 mg/kg as DXR. After 16 hours from the administration, a Nembutal injection solution (Dainippon Pharmaceutical Co., Ltd.) was intraperitoneally administered to the mice and thoracotomy was performed under anesthetization to collect blood. Blood plasma was separated and used for analysis of DXR.

100 μ L of the plasma was added with 1 mL of 0.3 M hydrochloric acid/50% ethanol (hydrochloric ethanol) and heated at 60°C for 10 minutes to extract DXR. The extract was cooled to 4°C and centrifuged at 15,000 rpm for 10 minutes to collect a supernatant. The sample was diluted 4 times with hydrochloric ethanol and its fluorescence was measured at a fluorescence wavelength of 590 nm with an excitation wavelength of 490 nm. A calibration curve was prepared by using DXR diluted with hydrochloric ethanol to known concentrations and used in quantification of DXR in plasma. The recovery of DXR from the mouse plasma was 95 to 98% in a range of 3.75 to 30 μ g/mL of DXR (Reference: Cancer Res., 47, 4471, 1989).

The average values (\pm standard deviation) of plasma DXR concentrations in the respective liposome groups are shown in Fig. 1. It was found that the plasma DXR concentration as an index of retention of the liposomes in blood increased depending on the amount of PEG bonded to the liposomes for both of PEG 5000 and PEG 2000.

Example 3: Preparation of liposome bonded with PEG and antibodies (pharmacokinetic test)

Liposomes introduced with PEG in an amount of 0 to 0.6 mole% based on the total lipids in the liposome, 0 to about 1 mole% based on DPPC and 0 to about 30 mole% based on maleimidated DPPE (encapsulating DXR, bonded with antibodies and PEG 5000) were prepared according to the method of Example 1.

<Table 2>

Liposome	DXR concentration (mg/100 mg lipids)	Antibody (mg/100 mg lipids)	PEG amount*	PEG amount**	PEG amount***
1	10.2	1.5	0	0	0
2	10.4	1.6	0.06	0.10	3
3	10.3	1.6	0.10	0.16	5
4	10.3	1.6	0.15	0.24	8
5	11.1	1.6	0.28	0.44	15
6	10.5	1.6	0.30	0.48	16
7	10.2	1.6	0.36	0.56	19
8	11.0	1.8	0.48	0.76	26
9	10.8	1.3	0.52	0.82	28
10	10.8	1.7	0.61	0.97	33

* Mole% based on total lipids

** Mole% based on one mole of DPPC

*** Mole% based on one mole of maleimidated lipid DPPE

DXR in blood plasma was quantified in the same manner as in Example 2. The average values (\pm standard deviation) of plasma DXR concentrations in the respective liposome groups are shown in Fig. 2. The plasma DXR concentration increased depending on the amount of PEG bonded to the liposomes, but it was found that the concentration reached a plateau at an introduced amount of PEG of about 0.3 mole% based on the total lipids, about 0.5 mole% based on DPPC, and about 17 mole% based on maleimidated DPPE. When DXR leaked from the liposomes, the leaked DXR was verified to rapidly disappear from blood, and accordingly, it is considered that the plasma DXR concentrations shown in the results in Examples 2 and 3 were attributable to DXR encapsulated in the liposomes.

Example 4: Preparation of liposome bonded with PEG and an antibody (efficacy test, pharmacokinetic test)

The following Liposomes 2 to 7, in which 0.5, 1.2, 2.0, 4.5, 5.3 and 11.4 mg of

antibodies were bonded to 100 mg of the total lipids of the liposome (encapsulating DXR , bonded with PEG 5000), were prepared according to the method of Example 1. In a similar manner, Liposomes 1 bonded with no antibody were prepared. In the PEG-bonded liposomes, retention of each liposome in blood was equivalent within the range of the amount of PEG bonded (> 4.4 mg/100 mg lipids). Therefore, the experimental results shown below depended on the bonded amount of antibodies.

<Table 3>

Liposome	Amount of bonded antibodies (mg/100 mg lipids)	Amount of included DXR (mg/100 mg lipids)	Amount of bonded PEG (mg/100 mg lipids)
1	0	9.5	8.2
2	0.5	9.1	8.2
3	1.2	9.5	8.1
4	2.0	8.9	5.3
5	4.5	9.6	6.2
6	5.3	9.7	6.4
7	11.4	10.0	3.2

Stomach cancer cell strain MKN45 was subcutaneously transplanted at two sites (1×10^6 cells per site) on the dorsal side of nude mice. For the "efficacy test", administrations of liposomes with different amounts of bonded antibodies were started when the tumor reached to a size large enough to measure its long and short diameters. The dose of the liposomes was 5.0 mg/kg (as the amount of DXR) per administration. A DXR-administered group (5.0 mg/kg) was provided as a positive control, and physiological saline was administered to the control group. All of the groups were intravenously administered on the day of the start of the administration (day 0), day 3 and day 6.

The diameters of the tumors (longer and shorter diameters) were measured with time and an estimated tumor weight ($(\text{shorter diameter})^2 \times \text{longer diameter} / 2$) was calculated. After the three times of administration, the measurement was continued until day 19. The tumor proliferation rate was calculated based on the estimated

weight of each tumor on the day of the start of the administration, which was taken as 1.0 to evaluate inhibitory effect on tumor proliferation of each treated group relative to the control group and the DXR-administered group. On the last day of the measurement (day 19), a %T/C value (tumor proliferation rate of treated group/tumor proliferation rate of control group $\times 100$) was calculated for each treated group. The amount of bonded antibodies which achieved the maximum inhibitory effect against tumor proliferation (an optimum dose) was obtained based on the amount of bonded antibodies in each sample.

As a result, significant inhibitory effects against tumor proliferation were found in all of the treated groups compared with the control group. As shown in Fig. 3, when comparison was made to the DXR-administered group, significant inhibitory effects against tumor proliferation were observed in the samples with the amounts of bonded antibodies within the range of 0.5 to 5.3 mg/100 mg of total lipids. The inhibitory activity against tumor proliferation was observed with a peak in the vicinity of 2 mg/100 mg of total lipids as the amount of bonded antibodies.

In the "pharmacokinetic test", the above Liposomes 4 to 7 with different amounts of bonded antibodies (2.0, 4.5, 5.3 and 11.4 mg/100 mg of total lipids) were intravenously administered to mice (each group consisted of 2 or 3 mice, 1.0 mg/kg as the amount of DXR amount). Four hours after the administration, blood plasma was collected from each animal. The amount of DXR in plasma was measured by the fluorescence measurement method in the same manner as in Example 2. The amounts of DXR in plasma in the respective samples after the administration were compared to found correlation between the amount of bonded antibodies and the retention in blood of the liposomes encapsulating DXR and bonded with antibodies. In the pharmacokinetic test, correlation between the DXR amount in plasma after administration of each sample and the amount of bonded antibodies of each sample was obtained for samples having the amount of the bonded antibodies of 2 mg/100 mg of lipids or more (Fig. 4). As a result, it was found that, when the amount of the bonded antibodies exceeded 2 mg/100 mg of the lipids, the retention in blood decreased depending on the increasing amount of the bonded antibodies.

Industrial Applicability

The liposome of the present invention is characterized by excellent retention in blood and a reduced amount of bonded polyalkylene glycol compared to conventional liposomes. Therefore, the liposome of the present invention can avoid side effects caused by polyalkylene glycol and has advantages from a viewpoint of industrial productivity. The liposome of the present invention is further characterized that the liposome can achieve more excellent therapeutic effect compared to conventional antibody-bonded liposomes.

0926350-010702

What is claimed is:

1. A liposome wherein a compound containing a polyalkylene glycol moiety is bonded through a thioether group to a liposome comprising lipids whose partial component has maleimidated terminal, and wherein an amount of the bonded compound is 15 to 50 mole% based on one mole of the maleimidated lipid contained in the liposome.

2. The liposome according to claim 1, wherein the amount of the bonded compound is 15 to 30 mole% based on one mole of the maleimidated lipids.

3. The liposome according to claim 1 or claim 2, which is obtained by reacting a maleimide group of the maleimidated lipid with the compound containing a polyalkylene glycol moiety introduced with a thiol group.

4. The liposome according to any one of claims 1 to 3, wherein the compound is bonded to a surface of the liposome.

5. The liposome according to any one of claims 1 to 4, wherein the polyalkylene glycol is polyethylene glycol.

6. The liposome according to claim 5, wherein the compound has two polyethylene glycol groups.

7. The liposome according to claim 6, wherein the polyethylene glycol has a molecular weight of 2,000 to 7,000 daltons.

8. The liposome according to claim 6, wherein the polyethylene glycol has a molecular weight of about 5,000 daltons.

9. The liposome according to any one of claims 1 to 8, wherein an antibody is further bonded on a surface of the liposome.

10. A liposome wherein an antibody is bonded through a thioether group to a liposome comprising lipids whose partial component has maleimidated terminal, and wherein an amount of the bonded antibody is 0.1 to 2 mole% based on one mole of the maleimidated lipids contained in the liposome.

11. The liposome according to claim 10, wherein an amount of the bonded antibody is 0.4 to 0.7 mole% based on one mole of the maleimidated lipids.

12. The liposome according to claim 10 or claim 11, which is obtained by reacting a liposome having a maleimide group and a sulfur-containing group deriving

from the antibody to form a thioether bond.

13. The liposome according to any one of claims 10 to 12, wherein the antibody is a GAH antibody,

14. The liposome according to any one of claims 10 to 13, wherein the antibody is a $F(ab')_2$ antibody fragment.

15. The liposome according to any one of claims 10 to 14, wherein a compound containing a polyalkylene glycol moiety is further bonded to a surface of the liposome.

16. A liposome wherein a compound containing a polyalkylene glycol moiety and an antibody are bonded through thioether groups to a liposome comprising lipids whose partial component has maleimidated terminal, and wherein an amount of the bonded compound is 15 to 30 mole% and an amount of the bonded antibody is 0.4 to 0.7 mole% based on one mole of the maleimidated lipids contained in the liposome.

17. The liposome according to claim 16, which is obtained by reacting a maleimide group of the maleimidated lipid with the compound containing a polyalkylene glycol moiety introduced with a thiol group.

18. The liposome according to claim 16 or claim 17, wherein the compound is bonded to a surface of the liposome.

19. The liposome according to any one of claims 16 to 18, wherein the polyalkylene glycol is polyethylene glycol.

20. The liposome according to claim 19, wherein the compound has two polyethylene glycol groups.

21. The liposome according to claim 20, wherein the polyethylene glycol has a molecular weight of 2,000 to 7,000 daltons.

22. The liposome according to claim 20, wherein the polyethylene glycol has a molecular weight of about 5,000 daltons.

23. The liposome according to any one of claims 16 to 22, which is a liposome obtained by reacting a liposome having a maleimide group and a sulfur-containing group deriving from the antibody to form a thioether bond.

24. The liposome according to any one of claims 16 to 23, wherein the antibody is a GAH antibody.

25. The liposome according to any one of claims 16 to 24, wherein the

antibody is a $F(ab')_2$ antibody fragment.

26. A medicament for treatment of cancer according to any one of claims 1 to 25.

27. The medicament according to claim 26, wherein the cancer is stomach cancer or colon cancer.

28. A method for treatment of cancer which comprises the use of the liposome according to any one of claims 1 to 27.

0926358.010702

Fig. 1




Fig. 2




Fig. 3





Fig.4



Declaration and Power of Attorney for Utility or Design Patent Application

特許出願宣言書

Japanese Language Declaration

私は、下欄に氏名を記載した発明者として、以下のとおり宣言する：

私の住所、郵便の宛先および国籍は、下欄に氏名に続いて記載したとおりであり、

名称の発明に関し、請求の範囲に記載した特許を求める主題の本来の、最初にして唯一の発明者である（一人の氏名のみが下欄に記載されている場合）か、もしくは本来の、最初にして共同の発明者である（複数の氏名が下欄に記載されている場合）と信じ、

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name:

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Liposome Bonded with Antibody and Polyalkylene Glycol

the specification of which is attached hereto unless the following box is checked:

☒ was filed on 20/Apr/00 as United States Application Number 09/926,358 and was amended on 22/Oct/01 (if applicable) or,

PCT International Application Number PCT/JP00/02596 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority under Title 35, United States Code §119(a-d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States, listed below. I have also identified below, by checking the "No" box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed:

上記発明の明細書（下記の欄で x 印がついていない場合は、本書に添付）は、

☐ 年 月 日に提出され、米国出願番号 _____ とし、（該当する場合）
年 月 日に訂正されました。又は、

特許協定条約国際出願番号 _____ とし、
（該当する場合） 年 月 日に訂正されました。

私は、前記のとおり補正した請求の範囲を含む前記明細書の内容を検討し、理解したことを陳述する。

私は、連邦規則法典第 37 編第 1 条 56 項に定義されているとおり、特許資格の有無について重要な情報を開示すべき義務があることを認めます。

私は、合衆国法典第 35 部第 119 条 (a-d) 項又は第 365 条 (b) 項に基づく、下記の外国特許出願又は発明者証出願、或いは第 365 条 (a) 項に基づく、少なくとも米国以外の 1 カ国を指名した PCT 国際出願の外国優先権を主張し、更に優先権の主張に係わる基礎出願の出願日前の出願日を有する外国特許出願、又は発明者証出願或るいは PCT 国際出願を以下に“なし”の箱に印をつけることにより明記する：

Prior foreign applications
先の外国出願

<u>11-115737</u>	<u>Japan</u>	<u>23/Apr/99</u>
(Number)	(Country)	(Day/Month/Year Filed)
(番号)	(国名)	(出願の年月日)

Priority claimed
優先権の主張

<input checked="" type="checkbox"/>	<input type="checkbox"/>
Yes	No
あり	なし

<u>11-115738</u>	<u>Japan</u>	<u>23/Apr/99</u>
(Number)	(Country)	(Day/Month/Year Filed)
(番号)	(国名)	(出願の年月日)

<input checked="" type="checkbox"/>	<input type="checkbox"/>
Yes	No
あり	なし

☐ その他の外国特許出願番号は別紙の追補優先権欄にて記載する。

☐ Additional foreign application numbers are listed on a supplemental priority sheet attached hereto.

Japanese Language Utility or Design Patent Application Declaration

私は、合衆国法典第 35 部第 119 条(e)項に基づく、下記の合衆国仮特許出願の利益を主張する。

I hereby claim the benefit under Title 35, United States Code §119 (e) of any United States provisional application(s) listed below.

(Application No.)

(出願番号)

(Day/Month/Year Filed)

(出願の年月日)

(Application No.)

(出願番号)

(Day/Month/Year Filed)

(出願の年月日)

(Application No.)

(出願番号)

(Day/Month/Year Filed)

(出願の年月日)

☐ その他の合衆国仮特許出願番号は別紙の追補優先権欄にて記載する。

☐ Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

私は、合衆国法典第 35 部第 120 条に基づく下記の合衆国特許出願、又は第 365 条(c)項に基づく合衆国を指名した PCT 国際出願の利益を主張し、本願の請求の範囲各項に記載の主題が合衆国法典第 35 部第 112 条第 1 項規定の態様で、先の合衆国特許出願又は PCT 国際出願に開示されていない限度において、先の出願の出願日と本願の国内出願日又は PCT 国際出願日の間に有効となった連邦規則法典第 37 部第 1 章第 56 条に記載の特許要件に所要の情報を開示すべき義務を有することを認める。

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s), or §365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

(Application No.)

(出願番号)

(Day/Month/Year Filed)

(出願の年月日)

(現況)

(特許済み、係属中 放棄済み)

(Status)

(patented, pending, abandoned)

(Application No.)

(出願番号)

(Day/Month/Year Filed)

(出願の年月日)

(現況)

(特許済み、係属中 放棄済み)

(Status)

(patented, pending, abandoned)

☐ その他の合衆国又は国際特許出願番号は別紙の追補優先権欄にて記載する。

☐ Additional U.S. or international application numbers are listed on a supplemental priority sheet attached hereto.

私は、ここに自己の知識に基づいて行った陳述が全て真実であり、自己の有する情報および信ずるところに従って行った陳述が真実であると信じ、さらに故意に虚偽の陳述等を行った場合、合衆国法典第 18 部第 1001 条により、罰金もしくは禁に処せられるか、またはこれらの刑が併科され、またかかる故意による虚偽による陳述が本願ないし本願に対して付与される特許の有効性を損なうことがあることを認識して、以上の陳述を行ったことを宣言する。

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

私、下記署名者は、ここに記載の米国弁護士または代理人に本出願に関し特許商標庁にて取られるいかなる行為に関して、同米国弁護士又は代理人が私に直接連絡なしに私の外国弁護士或いは法人代表者からの指示を受け取り、それに従うようここに委任する。この指示を出す者が変更の場合には、ここに記載の米国弁護士又は代理人にその旨通知される。

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from either his foreign patent agent or corporate representative, if any, as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

Japanese Language Utility or Design Patent Application Declaration

委任状： 私は、下記発明者として、下記に明記された顧客番号を伴う以下の弁護士又は、代理人をここに選任し、本願の手続きを遂行すること並びにこれに関する一切の行為を特許商標庁に対して行うことを委任する。そして全ての通信はこの顧客番号宛に発送される。

顧客番号 7055

POWER OF ATTORNEY: As a named inventor, I hereby appoint the attorney(s) and/or agent(s) associated with the Customer Number provided below to prosecute this application and transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

CUSTOMER NUMBER 7055

現在委任された弁護士は下記の通りである。

Neil F. Greenblum Reg. No. 28,394
 Bruce H. Bernstein Reg. No. 29,027
 James L. Rowland Reg. No. 32,674
 Arnold Turk Reg. No. 33,094

The appointed attorneys presently include:

Stephen M. Roylance Reg. No. 31,296
 William E. Lyddane Reg. No. 41,568
 William Pieprz Reg. No. 33,630
 Leslie J. Paperner Reg. No. 33,329

Address: GREENBLUM & BERNSTEIN, P.L.C.
 1941 Roland Clarke Place
 Reston, VA 20191

直接電話連絡先:

Direct Telephone Calls to:

GREENBLUM & BERNSTEIN, P.L.C.
 (703) 716-1191

唯一のまたは第一の発明者の氏名	Full name of sole or first inventor
Toshiaki TAGAWA	Toshiaki TAGAWA
発明者の署名	Inventor's signature
Toshiaki Tagawa	Toshiaki Tagawa
住所	Residence
Kanagawa, Japan	Kanagawa, Japan
国籍	Citizenship
Japan	Japan
郵便の宛先	Post Office Address
c/o Mitsubishi-Tokyo Pharmaceuticals, Inc., Yokohama Research Center, 1000, Kamoshida-cho, Aoba-ku, Yokohama-shi, Kanagawa 227-0033, Japan	c/o Mitsubishi-Tokyo Pharmaceuticals, Inc., Yokohama Research Center, 1000, Kamoshida-cho, Aoba-ku, Yokohama-shi, Kanagawa 227-0033, Japan
第二の共同発明者の氏名 (該当する場合)	Full name of second joint inventor, if any
Saiko HOSOKAWA	Saiko HOSOKAWA
同第二共同発明者の署名	Second Inventor's signature
Saiko Hosokawa	Saiko Hosokawa
住所	Residence
Kanagawa, Japan	Kanagawa, Japan
国籍	Citizenship
Japan	Japan
郵便の宛先	Post Office Address
c/o Mitsubishi-Tokyo Pharmaceuticals, Inc., Yokohama Research Center, 1000, Kamoshida-cho, Aoba-ku, Yokohama-shi, Kanagawa 227-0033, Japan	c/o Mitsubishi-Tokyo Pharmaceuticals, Inc., Yokohama Research Center, 1000, Kamoshida-cho, Aoba-ku, Yokohama-shi, Kanagawa 227-0033, Japan

(第三またはそれ以降の共同発明者に対しても同様な情報および署名を提供すること。)

(Supply similar information and signature for third and subsequent joint inventors.)